From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Overall | GOLD 2 | GOLD 3 | GOLD 4 | |
---|---|---|---|---|
Patients with both confirmed FEV1 decline and confirmed SGRQ deterioration, n (%) | 1344 (100.0) | 698 (100.0) | 575 (100.0) | 54 (100.0) |
On same assessment | 240 (17.9) | 121 (17.3) | 108 (18.8) | 9 (16.7) |
FEV1 decline before SGRQ deterioration | 620 (46.1) | 350 (50.1) | 239 (41.6) | 20 (37.0) |
SGRQ deterioration before FEV1 decline | 484 (36.0) | 227 (32.5) | 228 (39.7) | 25 (46.3) |
Moderate/severe exacerbation before FEV1 and SGRQ deterioration | 546 (40.6) | 246 (35.2) | 269 (46.8) | 24 (44.4) |
Patients with confirmed FEV1 decline and no confirmed SGRQ deterioration, n (%) | 1160 (100.0) | 644 (100.0) | 459 (100.0) | 46 (100.0) |
Moderate/severe exacerbation before FEV1 decline | 460 (39.7) | 231 (35.9) | 199 (43.4) | 24 (52.2) |
Unconfirmed SGRQ deterioration | 302 (26.0) | 180 (28.0) | 109 (23.7) | 10 (21.7) |
On same assessment as confirmed FEV1 decline | 34 (2.9) | 20 (3.1) | 12 (2.6) | 1 (2.2) |
Before confirmed FEV1 decline | 116 (10.0) | 72 (11.2) | 36 (7.8) | 7 (15.2) |
Patients with confirmed SGRQ and no confirmed FEV1 deterioration, n (%) | 995 (100.0) | 383 (100.0) | 479 (100.0) | 124 (100.0) |
Moderate/severe exacerbation before SGRQ deterioration | 574 (57.7) | 184 (48.0) | 305 (63.7) | 80 (64.5) |
Unconfirmed FEV1 deterioration | 284 (28.5) | 141 (36.8) | 126 (26.3) | 15 (12.1) |
On same assessment as confirmed SGRQ deterioration | 50 (5.0) | 23 (6.0) | 24 (5.0) | 3 (2.4) |
Before confirmed SGRQ deterioration | 151 (15.2) | 80 (20.9) | 64 (13.4) | 5 (4.0) |